Study of Disulfiram to Reduce Myeloid Immunosuppression and Steroid Dependence in Resectable High Grade Glioma

This research study is for participants with glioblastoma. It can cause a tumor immunosuppression which helps myeloid cells that can stop T-cell function. Disulfiram is a drug that has been used in treating other disorders, but this study will examine if disulfiram can help make the tumor environment less immunosuppressive and reduce brain swelling when taken before surgery.

Inclusion Criteria: * Age ≥18 years. * Radiographically suspected or confirmed high-grade glioma planned for surgical resection as part of standard clinical care. * Able to start disulfiram at least 3 days prior to planned surgery (treatment window 3-14 days pre-op). * In-patient status for the duration of study. * Karnofsky Performance Status (KPS) ≥70%. * Adequate organ function within 14 days prior to first dose: * ANC ≥1.5 x 10\^9/L * Platelets ≥100 x 10\^9/L * Hemoglobin ≥9 g/dL * AST/ALT ≤2.5 x ULN * Total bilirubin ≤1.5 x ULN (unless Gilbert syndrome, in which case \